This article originally appeared www.rbht.nhs.uk
“Royal Brompton & Harefield NHS Foundation Trust has become the first organisation in Europe to recruit patients for an important new study which looks at the potential for a new drug to be used in the treatment of Cystic Fibrosis.
The drug under study, known simply as FDL169, has already been shown to improve the function of the protein which is defective in patients with CF.
CF is an inherited condition where the lungs and digestive system become clogged with thick, sticky mucus which can cause problems with breathing and digestion from a young age. Over many years, the lungs become increasingly damaged and may eventually stop working properly. The condition affects over 70,000 people worldwide with an estimated 1 in every 2,500 babies in the UK being born with the condition.
The aim of this study is to see how safe the drug is and how it interacts with the body, with one group of patients receiving differing doses of the experimental drug and another group of patients receiving a placebo (a dummy drug). The drug is planned as a long-term treatment in a specific subset of patients with CF who have the most common genetic mutation (F508del-CFTR mutation).
The study is currently being undertaken at 14 sites across the world including Australia, Germany, Czech Republic and the UK, and is sponsored by Flatley Discovery Laboratory, a not-for-profit laboratory for CF drug discovery, based in the United States…”
To read the full article, please visit http://www.rbht.nhs.uk/research/research-news-2/trust-recruits-patient-in-europe-for-international-cf-study/.